Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siponimod and Chronic Intrathecal Inflammation in Progressive MS
2024-512283-65-00Phase 4Authorised
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of siponimod in secondary-progressive multiple sclerosis (SPMS), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Change in cerebrospinal fluid CXCL13 levels. Planned start Aug 2024; status: authorised.
02
Drugs
siponimod
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2024-512283-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512283-65-00.